Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study
- PMID: 20039404
- PMCID: PMC2857977
- DOI: 10.1002/art.27189
Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study
Abstract
Objective: To understand the effects of long-term BLyS inhibition in human systemic lupus erythematosus (SLE).
Methods: Seventeen patients with SLE who were enrolled in a clinical trial of belimumab, a BLyS-specific inhibitor, plus standard of care therapy were studied. Phenotypic analysis of lymphocytes was performed using flow cytometry. Circulating antibody-secreting cells were enumerated using enzyme-linked immunospot assay. Serum was analyzed by enzyme-linked immunosorbent assay using an antibody that recognizes products of the V(H)4-34 gene. Lymphocyte counts, Ig levels, and anti-double-stranded DNA antibody levels were available as part of the clinical trial analyses.
Results: Samples were collected on days 0, 84, 168, 365, and 532 and after day 730. The total number of B cells started to decrease from baseline between days 84 and 168. This was due to a decrease in naive and transitional B cells. CD27+IgD+ memory B cells and plasmablasts decreased only after 532 days, whereas CD27+IgD- memory B cells were not affected, and there were no changes in T cells. Serum IgM levels began to decline between days 84 and 168, but there were no changes in serum levels of IgG, IgG anti-DNA antibodies, or V(H)4-34 antibodies during the study. SLE patients had more IgM-, IgG-, and autoantibody-producing B cells than did normal controls on day 0. There was only a modest decrease in the frequency of total IgM-producing, but not IgG-producing, cells on days 365 and 532, consistent with the phenotypic and serologic data.
Conclusion: Our data confirm the dependence of newly formed B cells on BLyS for survival in humans. In contrast, memory B cells and plasma cells are less susceptible to selective BLyS inhibition.
Trial registration: ClinicalTrials.gov NCT00071487.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2857977/bin/nihms190573f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2857977/bin/nihms190573f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2857977/bin/nihms190573f3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2857977/bin/nihms190573f4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2857977/bin/nihms190573f5.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2857977/bin/nihms190573f6.gif)
Similar articles
-
Belimumab for the treatment of systemic lupus erythematosus.Expert Rev Clin Immunol. 2015 Feb;11(2):195-204. doi: 10.1586/1744666X.2015.996550. Epub 2014 Dec 29. Expert Rev Clin Immunol. 2015. PMID: 25543845 Review.
-
Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.Lupus. 2013 Apr;22(4):361-71. doi: 10.1177/0961203312471575. Lupus. 2013. PMID: 23553779 Review.
-
Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.Arthritis Rheum. 2012 Jul;64(7):2328-37. doi: 10.1002/art.34400. Arthritis Rheum. 2012. PMID: 22275291 Free PMC article. Clinical Trial.
-
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.Arthritis Rheum. 2011 Dec;63(12):3918-30. doi: 10.1002/art.30613. Arthritis Rheum. 2011. PMID: 22127708 Free PMC article. Clinical Trial.
-
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.Arthritis Res Ther. 2008;10(5):R109. doi: 10.1186/ar2506. Epub 2008 Sep 11. Arthritis Res Ther. 2008. PMID: 18786258 Free PMC article. Clinical Trial.
Cited by
-
Combination of anti-SSA/Ro60 and anti-dsDNA serotype is predictive of belimumab renal response in patients with lupus nephritis.Lupus Sci Med. 2024 May 28;11(1):e001156. doi: 10.1136/lupus-2024-001156. Lupus Sci Med. 2024. PMID: 38806217 Free PMC article.
-
Effect of BAFF blockade on the B cell receptor repertoire and transcriptome in a mouse model of systemic lupus erythematosus.Front Immunol. 2024 Jan 9;14:1307392. doi: 10.3389/fimmu.2023.1307392. eCollection 2023. Front Immunol. 2024. PMID: 38264661 Free PMC article.
-
Belimumab treatment of adult idiopathic inflammatory myopathy.Rheumatology (Oxford). 2024 Mar 1;63(3):742-750. doi: 10.1093/rheumatology/kead281. Rheumatology (Oxford). 2024. PMID: 37326854 Free PMC article. Clinical Trial.
-
Expression of S100A8 protein on B cells is associated with disease activity in patients with systemic lupus erythematosus.Arthritis Res Ther. 2023 May 10;25(1):76. doi: 10.1186/s13075-023-03057-z. Arthritis Res Ther. 2023. PMID: 37165399 Free PMC article.
-
The rapid inhibition of B-cell activation markers by belimumab was associated with disease control in systemic lupus erythematosus patients.Front Pharmacol. 2023 Feb 16;14:1080730. doi: 10.3389/fphar.2023.1080730. eCollection 2023. Front Pharmacol. 2023. PMID: 36873989 Free PMC article.
References
-
- Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol. 2001;2(9):764–766. - PubMed
-
- Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004;20(6):785–798. - PubMed
-
- Lesley R, Xu Y, Kalled SL, Hess DM, Schwab SR, Shu HB, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity. 2004;20(4):441–453. - PubMed
-
- Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med. 2007;13(5):543–551. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- R37 AI049660/AI/NIAID NIH HHS/United States
- U19 AI056362-010001/AI/NIAID NIH HHS/United States
- R01 AR049938-05/AR/NIAMS NIH HHS/United States
- U19 AI056362/AI/NIAID NIH HHS/United States
- R01-AI049660/AI/NIAID NIH HHS/United States
- R01 AR049938/AR/NIAMS NIH HHS/United States
- U19 AI056390/AI/NIAID NIH HHS/United States
- U19-56-390/PHS HHS/United States
- P01-AI-51392/AI/NIAID NIH HHS/United States
- P01 AI078907/AI/NIAID NIH HHS/United States
- U19-AI-56362/AI/NIAID NIH HHS/United States
- R01-AR-049938-01/AR/NIAMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous